Advertisement

Should Oxaliplatin Be Added to 5FU-Based Regimens in Adjuvant Chemotherapy for Locally Advanced Rectal Cancer?

  • Alberto Sobrero
  • Alessandro Pastorino
Chapter

Abstract

The question represents an issue of active debate. In fact, on one hand, three options are pursued by oncologists following appropriate locoregional management of locally advanced rectal cancer: no additional adjuvant chemotherapy, fluoropyrimidines alone, and oxaliplatin-based adjuvant chemotherapy. On the other hand, the last version of US National Comprehensive Cancer Network guidelines recommends the use of FOLFOX or XELOX as adjuvant treatment for stage II/III rectal cancer, irrespective of the locoregional treatment delivered [1]. The appropriate definitive answer to the question regarding the role of adjuvant oxaliplatin can be given by a trial that, after optimal locoregional management including completion of preoperative chemoradiotherapy and subsequent TME, randomizes patients with pathological stage II/III rectal cancer, therefore pathologically staged, to receive adjuvant FOLFOX/XELOX versus fluorouracil/capecitabine alone. Actually, this trial exists. It is the Korean phase II randomized ADORE trial, recently published [2]. However, in order to adequately answer such an important question, at least one appropriately powered phase III trial is needed, not just a phase II as the Korean study. Because other phase III trials with similar (not identical) designs exist, we will consider the results of these trials as well.

References

  1. 1.
    NCCN Clinical Practige Guidelines in Oncology (NCCN Guidelines). Rectal Cancer. Version 3.2015, 06/18/2015. National Comprehensive Cancer NetworkGoogle Scholar
  2. 2.
    Hong YS, Ho Nam B, Kim KP et al (2014) Oxaliplatin, fluorouracil, and leucovorin versus fluorouracilandleucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 15:1245–1253CrossRefPubMedGoogle Scholar
  3. 3.
    Rödel C, Liersch R, Becker H et al (2012) Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 13(7):679–687CrossRefPubMedGoogle Scholar
  4. 4.
    Rödel C, Liersch T, Fietkau R et al (2015) Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 16(8):979–989CrossRefPubMedGoogle Scholar
  5. 5.
    Schmoll HJ, Haustermans K, Price T et al. (2014) Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine + oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: early results of the PETACC 6 trial. ASCO meeting 2014Google Scholar
  6. 6.
    Glynne-Jones R, Counsell N, Quirke P et al (2014) Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvantchemoradiationrandomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol 25:1356–1362CrossRefPubMedGoogle Scholar
  7. 7.
    Ryan PD, Hong S (2015) Adjuvant chemotherapy for locally advanced rectal cancer: is it a given? J Clin Oncol 33(17):1878–1880CrossRefPubMedGoogle Scholar
  8. 8.
    Petersen SH, Harling H, Kirkeby LT et al (2012) Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 3:CD004078Google Scholar
  9. 9.
    QUASAR Collaborative Group (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370:2020–2029CrossRefGoogle Scholar
  10. 10.
    Sakamoto J, Hamada C, Yoshida S et al (2007) An individual patient data meta-analysis of adjuvant therapy with uracil–tegafur (UFT) in patients with curatively resected rectal cancer. Br J Cancer 96(8):1170–1177CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Bosset JF, Calais G, Mineur L et al (2014) Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 15:184–190CrossRefPubMedGoogle Scholar
  12. 13.
    Sainato A, Cernusco V, Valentini V et al (2014) No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvantchemoradiotherapy in locally advanced cancer of therectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother Oncol 113:223–229CrossRefPubMedGoogle Scholar
  13. 14.
    Breugom AJ, van Gijn W, Muller EW et al (2015) Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol 26:696–701CrossRefPubMedGoogle Scholar
  14. 15.
    Breugom AJ, Swets M, Bosset JF et al (2015) Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16:200–207CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2018

Authors and Affiliations

  1. 1.IRCCS San Martino ISTGenoaItaly

Personalised recommendations